|
O.G. Filimonova
Features of the management of a patient with postmenopausal osteoporosis and vitamin D deficiency: a clinical case
|
№12 / 2021
|
|
E.A. Kulyaev (1), A.V. Grafov (1), O. V. Falameeva (1), V.S. Kholodkin (1), M.A Sadovoy (1, 2), O.V. Tsygankova (2)
EXPERIENCE OF THE USE OF ZOLEDRONIC ACID (REZOLLASTIN 5 MG/6.25 ML, OOO «NATIVA») IN PATIENTS WITH LOW BONE MINERAL DENSITY IN THE SETTINGS OF THE CENTER FOR PREVENTION OF OSTEOPOROSIS OF NOVOSIBIRSK SRITO
|
№19 / 2017
|
|
A.Yu.Kochish, MD, S.N. Ivanov
COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF DOMESTIC GENERICS AND ORIGINAL DRUG OF ZOLEDRONIC ACID IN PATIENTS WITH LOW-ENERGY VERTEBRAL FRACTURES AND POSTMENOPAUSAL OSTEOPOROSIS
|
№s5-14 / 2014
|
|
E.G. Zotkin
SOME FEATURES OF TREATMENT OF INVOLUTIONAL OSTEOPOROSIS USING BISPHOSPHONATES IN ELDERLY PATIENTS
|
№7 / 2014
|
|
I.G.Rusakov, A.A.Kosov, S. V. Mishugin
Place Of Drug Therapy In The Prevention And Treatment Of Bone Complications Of Prostate Cancer
|
№18 / 2012
|
|
P.V .Glybochko, Yu.G. Alyaev, A.Z. Vinarov, Yu.L. Demidko, O.V. Zelenova, Ye.V. Shpot
Bone Metabolism And Effectiveness Of Zoledronic Acid In Locally Advanced And Disseminated Prostate Cancer
|
№7 / 2011
|
|
L.Yu. Vladimirova, N.A. Abramova, A.E Storozhakova, A.L. Paly
Resorba In The Treatment Of Bone Metastasis Of Breast Cancer
|
№17 / 2010
|
|
N.V. Zhukov
Drug Zometa In Addition To The Chemotherapy Significantly Increases Overall Survival In Previously Untreated Patients With Multiple Myeloma
|
№17 / 2010
|
|
Bolotina L.V.
Modern possibility of bisphosphonates use in complex treatment of hormonedependent tumors
|
№6 / 2010
|
|
I.S. Krysanov
Bone Metastasis Of Breast Cancer: How Much Does Bisphosphonate Therapy Cost?
|
№18 / 2009
|
Русский
